Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CD20 Antigens

Known as: Antigens, CD20, Antigens, CD20 [Chemical/Ingredient], CD20 
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell… Expand
National Institutes of Health

Related topics

Related topics

7 relations
CD20 Ag:PrThr:Pt:Tiss:Ord:Immune stainIn BloodMS4A1 geneMS4A1 wt Allele
Expand

Narrower (1)

Human B-Lymphocyte Antigen CD20, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
  • C. Choi, Y. Park, +6 authors Y. Chu
  • Journal of pathology and translational medicine
  • 2016
    • Corpus ID: 16322059
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
2016
2016
Vyřazení genu CD20 pomocí CRISPR/Cas9 knockoutu nezpůsobí žádnýdefekt v BCR signalizaci u B-lymfoidních malignit
 
Highly Cited
2016
Highly Cited
2016
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL…
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2015
2015
Water-soluble nanoconjugates of quantum dot-chitosan-antibody for in vitro detection of cancer cells based on "enzyme-free" fluoroimmunoassay.
Cancer remains one of the world's most devastating diseases with millions of fatalities and new cases every year. In this work… Expand
2014
2014
Fluorescent nanohybrids based on quantum dot-chitosan-antibody as potential cancer biomarkers.
Despite undeniable advances in medicine in recent decades, cancer is still one of the main challenges faced by scientists and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
Development of a mimotope-based vaccine against CD20 antigen.
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to… Expand
2004
2004
Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces.
Here we report that B cell receptor (BCR) engagement rapidly improves the capacity of CD20 to be accessed by cognate antibody at… Expand
2001
2001
Combination of CpG and antibodies to CD19, CD20, CD22 or CD40 in the prevention or treatment of cancer.
 
Highly Cited
1999
Highly Cited
1999
Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
Cutaneous marginal zone lymphoma (MZL) is a recently described low-grade B-cell lymphoma that usually follows an indolent course… Expand
1992
1992
IL-4 induces conformational change of CD20 antigen via a protein kinase C-independent pathway. Antagonistic effect of anti-CD40 monoclonal antibody.
The CD20 molecule is a unique phosphoprotein exclusively expressed on B cells during most stages of B cell ontogeny. We here… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE